|
- 积分
- 299
- 威望
- 299
- 包包
- 1702
|
Mol Ther. 2011 Mar;19(3):584-93. Epub 2010 Nov 30.6 X4 P! D# b$ C
+ E1 D0 v' s8 i5 [* t6 ^+ t! v
Generation of HIV-1 Resistant and Functional Macrophages From Hematopoietic Stem Cell-derived Induced Pluripotent Stem Cells.
8 \0 _9 K0 [4 f3 GKambal A, Mitchell G, Cary W, Gruenloh W, Jung Y, Kalomoiris S, Nacey C, McGee J, Lindsey M, Fury B, Bauer G, Nolta JA, Anderson JS.
8 K* |. V/ R) q9 @' A( T7 F. r. Q2 e5 Y2 C( ]
Stem Cell Program, Department of Internal Medicine, University of California, Davis, Sacramento, California, USA.. _, L6 `% ]! j
. d# v. q$ c8 e, u# y& B. z+ q* GAbstract E# l! v* {0 m% {
Induced pluripotent stem cells (iPSCs) have radically advanced the field of regenerative medicine by making possible the production of patient-specific pluripotent stem cells from adult individuals. By developing iPSCs to treat HIV, there is the potential for generating a continuous supply of therapeutic cells for transplantation into HIV-infected patients. In this study, we have used human hematopoietic stem cells (HSCs) to generate anti-HIV gene expressing iPSCs for HIV gene therapy. HSCs were dedifferentiated into continuously growing iPSC lines with four reprogramming factors and a combination anti-HIV lentiviral vector containing a CCR5 short hairpin RNA (shRNA) and a human/rhesus chimeric TRIM5α gene. Upon directed differentiation of the anti-HIV iPSCs toward the hematopoietic lineage, a robust quantity of colony-forming CD133(+) HSCs were obtained. These cells were further differentiated into functional end-stage macrophages which displayed a normal phenotypic profile. Upon viral challenge, the anti-HIV iPSC-derived macrophages exhibited strong protection from HIV-1 infection. Here, we demonstrate the ability of iPSCs to develop into HIV-1 resistant immune cells and highlight the potential use of iPSCs for HIV gene and cellular therapies.
7 C$ B% Z9 y- n! E- T# Q" c0 q; n, b5 p# D4 n* U( n
|
-
总评分: 威望 + 2
包包 + 5
查看全部评分
|
发表于 2011-3-24 15:13
